Hansa Biopharma Ab · OMXSTO:HNSA
Hansa Biopharma Ab — Q1 2022 Earnings Presentation
15 slides from Hansa Biopharma Ab's earnings presentation, Apr 21, 2022
Slide 1: Conference Call Presentation Interim Report Q1 2022
Conference Call Presentation Interim Report Q1 2022 Lund, April 21, 2022
Slide 2: Forward-looking statements
Forward-looking statements This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occ
Slide 3: Highlights for the first quarter of 2022
Solid sales growth reported in Q1’22; Market access secured in Germany and France; Marketing authorization granted in Israel Highlights for the first quarter of 2022 ü Launch activities and market access efforts in EU progressing as planned - Solid sales growth in Q1 with SEK 24.2m in product sales;
Slide 4: Full commercial access secured in Germany; market access granted in France
Full commercial access secured in Germany; Market access granted in France through a reimbursed Early Access Program Market access procedures ongoing in 11 countries incl. Spain, Italy and the U.K. During 2021 market access was secured in Sweden and Netherlands as well as on an individual hospital b
Slide 5: Commercial sales uptake
Our center focused and sequenced launch process will help build the foundation for Idefirix® to become a new Standard of Care in transplantation Idefirix® is the first and only approved treatment in Europe for desensitization treatment of highly sensitized kidney transplant patients. The long-term m
Slide 6: Results from Phase 2 study of imlifidase in anti-GBM disease published in JASN
Results from Phase 2 study of imlifidase in anti-GBM disease published in Journal of American Society of Nephrology Nephrology (JASN)1 U.S. FDA has accepted Hansa’s Investigational New Drug (IND) application to proceed with a Phase 3 study of imlifidase in 50 patients across U.S. and EU with the fir
Slide 7: Continuous progress in our ongoing clinical programs
Continuous progress in our ongoing clinical Programs Enrollment status Enrollment status April 20, 2022 April 20, 2022 Antibody Mediated Rejection Phase 2 study Anti-GBM Phase 3 study • 28/30 patients enrolled in the AMR phase 2 study • U.S. FDA has accepted Hansa’s Investigational New • Completion
Slide 8: Broad clinical pipeline in transplantation and auto-immune diseases
Broad clinical pipeline in transplantation and auto-immune diseases Candidate/ Research/ Marketing Program Indication Preclinical Phase 1 Phase 2 Phase 3 Authorization Marketed Next Anticipated Milestone EU: Additional agreements EU: Kidney transplantation in highly sensitized patients 1,2 *) around
Slide 9: Solid sales growth in Q1 2022 - product sales of SEK 24.2m
Solid sales growth in Q1’2022 - product sales of SEK 24.2m Revenue (Q/Q) Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 30,3 Product sales 15,4 24,2 SEKm 9,0 9,0 6,0 4,5 4,9 3,6 5,3 5,2 Revenue recognition Sarepta 2,4 4,4 0,8 0,5 0,9 0,6 1,1 Axis-Shield Revenue (FY/FY) 2019 2020 2021 33,9 Product sales 15,0 SEKm Rev
Slide 10: Continued investments in our commercialization and pipeline
Continued investments in our commercialization and pipeline SG&A expenses (Q/Q) R&D expenses (Q/Q) Net loss (Q/Q) Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 -60 -81 -83 -80 -47 -103 -55 -104 -61 SEKm SEKm SEKm -68 -71 -133 -138 -148 -163 SG&A expenses (
Slide 11: Operations financed into 2023
With current cash position and projected burn-rate, Hansa’s operations are financed into 2023 Operating cash flow (Q/Q) Cash & short-term investments (Q/Q) Shareholders’ equity (Q/Q) Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 -113 -116 SEKm -121 -132 -130 1 255 1 139 1 007 889 SEKm 754 1 150 1 031 900 758 636 SE
Slide 12: Upcoming milestones
Upcoming milestones Milestones subject to potential COVID-19 impact Long-term follow- Anti-GBM Kidney transplantation GBS up data 5-years Kidney Initiation of U.S. complete Phase 2 complete out in kidney transplantation Phase 3 study enrollment enrollment transplantation U.S. BLA submission (2022) (
Slide 13: Q&A
Q&A … at Hansa Biopharma we envision a world Visit our web site www.hansabiopharma.com where all patients with rare immunologic diseases can lead long and healthy lives… 13
Slide 14: Corporate Contacts
Corporate Contacts Visit our web site Investor Relations and www.hansabiopharma.com Corporate Communications Calendar and events April 21 2022 Kempen Life Sciences Conference 2022, Amsterdam Klaus Sindahl April 27 2022 Redeye Orphan Drugs 2022, Stockholm Head of Investor Relations May 15 2022 ABG Li
Slide 15: HANSAT
MZ HANSAT BIOPHARMA